Clovis Oncology, Inc. (NASDAQ:CLVS) is on recovery track with 109.39% gain from a 1-year low price of $11.5. The company lost -2.9% to attain the price of $24.08 on 01/11/2019. Throughout the recent session, the prices were hovering between $23.96 and $24.75. These shares are 12.54% off its target price of $27.1 and the current market capitalization stands at $1.31B. The recent change has given its price a 34.27% lead over SMA 50 and -63.5% deficit over its 52-week high. The stock witnessed 12.1% gains, -15.18% declines and -49.63% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CLVS’s volatility during a week at 9.52% and during a month it has been found around 9%.Clovis Oncology, Inc. (CLVS) Top Holders
Institutional investors currently hold around $1.33 billion or 0% in CLVS stock. Look at its top three institutional owners. Palo Alto Investors Lp owns $125.72 million in Clovis Oncology, Inc., which represents roughly 9.6% of the company’s market cap and approximately 9.49% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 4,445,064 shares of the stock are valued at $107.04 million. The third largest holder is Blackrock Inc., which currently holds $103.83 million worth of this stock and that ownership represents nearly 7.93% of its market capitalization.Clovis Oncology, Inc. 13F Filings
At the end of September reporting period, 101 institutional holders increased their position in Clovis Oncology, Inc. (NASDAQ:CLVS) by some 6,432,681 shares, 105 decreased positions by 5,796,983 and 31 held positions by 42,798,904. That puts total institutional holdings at 55,028,568 shares, according to SEC filings. The stock grabbed 28 new institutional investments totaling 590,383 shares while 43 institutional investors sold out their entire positions totaling 1,917,096 shares.Clovis Oncology, Inc. (NASDAQ:CLVS) Insider Trades
Multiple company employees have indulged in significant insider trading. Clovis Oncology, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Rolfe Lindsey has sold 1,728 shares of Clovis Oncology, Inc. (CLVS) in trading session dated Dec. 20, 2018. These shares are worth $30,620 and were traded at $17.72 each. The SEC filing shows that Ivers-Read Gillian C performed a sale of 829 shares. The disposed these shares by way of transaction on Dec. 20, 2018. The company’s shares were given away at $17.72 per share worth to an income of some $14,690 on account of Ivers-Read Gillian C.
, Rolfe Lindsey, sold 284 common shares of Clovis Oncology, Inc. (CLVS) in the open market. In a transaction dated Dec. 04, 2018, the shares were put up for sale at an average price of $21.23, raking in a sum of $6,029. After this sale, 14,162 common shares of CLVS are directly owned by the insider, with total stake valued at $341,021.
In the transaction dated Dec. 04, 2018, the great number of shares disposed came courtesy the; Muehl Daniel W disposed a total of 188 shares at an average price of $21.23, amounting to approximately $3,991. The insider now directly owns 5,664 shares worth $136,389.Clovis Oncology, Inc. (CLVS) Analyst Guide
Several analysts have released their opinion on Clovis Oncology, Inc. (NASDAQ:CLVS), with 3 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.